FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2021 Results - Earnings Call Transcript

Aug. 09, 2021 8:30 PM ETFibroGen, Inc. (FGEN)
SA Transcripts profile picture
SA Transcripts
133.94K Followers

FibroGen, Inc. (NASDAQ:FGEN) Q2 2021 Results Conference Call August 9, 2021 5:00 PM ET

Company Participants

Michael Tung - Vice President of Corporate Strategy and Investor Relations

Enrique Conterno - Chief Executive Officer

Pat Cotroneo - Chief Financial Officer

Mark Eisner - Chief Medical Officer

John Hunter - Chief Scientific Officer

Thane Wettig - Chief Commercial Officer

Chris Chung - Senior Vice President of China Operations

Conference Call Participants

Michael Yee - Jefferies

Annabel Samimy - Stifel

Geoffrey Porges - SVB Leerink

Edwin Zhang - H.C. Wainwright

Yaron Werber - Cowen and Company

Andy Hsieh - William Blair

Difei Yang - Mizuho Securities

Charles Ferranti - Goldman Sachs

Operator

Good day, and thank you for standing by. Welcome to the FibroGen Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Michael Tung. Please go ahead.

Michael Tung

Thank you, Charlie. Good afternoon, everyone, and welcome to FibroGen's 2021 Second Quarter Conference Call. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; Pat Cotroneo, our Chief Financial Officer; Dr. Mark Eisner, our Chief Medical Officer; Dr. John Hunter, our Chief Scientific Officer; Thane Wettig, our Chief Commercial Officer; and Chris Chung, our Senior Vice President of China Operations. The format for today's call includes prepared remarks from Enrique and Pat, after which we will open up the call for Q&A.

I would like to remind you that remarks made on today's call may include forward-looking statements based on FibroGen's current expectations. Such statements may include statements regarding

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.